

## *Method for in vitro memory B lymphocyte expansion in culture and polyclonal IgG production*

Applications: Long-term *in vitro* expansion of memory B lymphocytes in culture and **production of immunoglobulin G (IgG)** for diagnostic or therapeutic applications.

Commercial interest: Biopharmaceutical, immunology, immunotherapy and cellular therapy companies.

Summary: This technology refers to a method for selecting populations of memory B lymphocytes (IgG<sup>+</sup>IgM<sup>-</sup>IgD<sup>-</sup> and IgA<sup>+</sup>IgM<sup>-</sup>IgD<sup>-</sup>) that are substantially depleted of naïve B lymphocytes (IgM<sup>+</sup> and/or IgD<sup>+</sup>). Culture of the selected B lymphocytes in the presence of a CD40 signal and appropriate cytokines allow **long-term (≥ 60 days) expansion of the cells**; after 60 days of culture, fold expansion is at least 10<sup>6</sup>, and can reach 10<sup>9</sup> if culture is extended to 70 days. **Cellular viability** remains above 80% throughout the culture period. This system allows the **production of polyclonal immunoglobulins** composed of at least 70% IgG, while IgM content does not exceed 10%. Given the high immunoglobulin secretion rate of the cells grown according to this method, final IgG concentrations in the culture supernatant reach at least 10 µg/ml. The relative proportions of the different Ig classes and subclasses are very similar to those of human plasma and of commercial preparations of therapeutic immunoglobulin. Additionally, the resulting memory B-lymphocyte populations could be used for the derivation of B-cell clones of desired specificity, as well as for the preparation of professional antigen-presenting cells for cellular therapy applications.

Intellectual Property: The following patents have been granted: CA 2,738,176, and US 8,703,486.

Assignees: Héma-Québec (Montréal, QC), and Université Laval (Québec, QC), CANADA.

Information about this technology, available for licensing, can be obtained from:

Jean-François Leblanc, M.Sc.

Scientific Information Specialist

Division of Medical Affairs and Innovation

HÉMA-QUÉBEC

1070, av. des Sciences-de-la-Vie

Québec (Québec), CANADA, G1V 5C3

Tel.: 418 780-4362 ext. 3281, or toll-free (Canada and the U.S.) 1-800-267-9711 ext. 3281

Email: [Jean-Francois.Leblanc@hema-quebec.qc.ca](mailto:Jean-Francois.Leblanc@hema-quebec.qc.ca)